In vitro activity of ceftobiprole and dalbavancin against a collection of coagulase-negative staphylococci isolates from clinical samples with reduced susceptibility to daptomycin and/or resistant to linezolid or glycopeptides

Fuente, Silvia Velasco de la; Fernández-Martinez, Marta; Rodríguez Lozano, Jesús; Pablo-Marcos, Daniel; Siller, María; Calvo Montes, Jorge.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 41(9): 567-570, Nov. 2023. tab
Artículo en Inglés | IBECS (España) | ID: ibc-227273

Documentos relacionados

  1. In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model.
  2. Molecular Characterization of Baseline <i>Enterobacterales</i> and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial.
  3. Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia.
  4. Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study.
  5. Ceftolozane-tazobactam in nosocomial pneumonia.
  6. Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects.
  7. [Nosocomial pneumonia: The end of the «â€…all Tazobac ¼ and the refinement of antibiotic treatment].
  8. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
  9. In vitro activity of ceftobiprole and dalbavancin against a collection of coagulase-negative staphylococci isolates from clinical samples with reduced susceptibility to daptomycin and/or resistant to linezolid or glycopeptides.
  10. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.